UPDATE : Tuesday, October 15, 2019
Handok releases Fabry disease treatment
Handok said Tuesday that it has rolled out Galafold, a Fabry disease treatm...
by Lee Han-soo  |  2019-07-02 16:19
26 new drugs approved in H1
Twenty-six new pharmaceutical products received approval in Korea in the fi...
by Lee Hye-seon  |  2019-07-02 14:31
[News Focus]Yuhan pulled off $3.1 billion licensing deals in one year. How?
Yuhan Corp. recently made headlines by signing an $870 million licensing de...
by Jeong Sae-im  |  2019-07-02 12:11
Huons launches new osteoarthritis treatment
Huons said that it has launched “Hi Hyal Once,” an osteoarthritis treatment...
by Lee Han-soo  |  2019-07-01 15:13
Eli Lilly Korea gains further reimbursement for psoriasis treatment Taltz
The Korean branch of Eli Lilly said that it had gained additional reimburse...
by Lee Han-soo  |  2019-07-01 14:27
BMS Korea files administrative suit to appeal Eliquis price cut
The price reduction of BMS Korea Pharmaceutical’s blood thinner Elidquis ha...
by Kim Yun-mi  |  2019-07-01 14:16
Yuhan signs $870 million licensing deal with Boehringer Ingelheim
Yuhan announced a joint development and licensing agreement with Boehringer...
by Lee Han-soo  |  2019-07-01 14:09
'Proteogenomics will improve ability to prevent, diagnose and treat cancer at molecular level'
With recent advancements in sequencing technologies, scientists are no long...
by Lee Han-soo  |  2019-06-28 17:43
Lilly anticipates Trulicity’s growth as GLP-1 receptor antagonists get popular
As physicians have increasingly recommended glucagon-like peptide-1 (GLP-1)...
by Kim Yun-mi  |  2019-06-28 16:12
Samsung Bioepis readies phase-3 trial on Soliris biosimilar
Samsung Bioepis is speeding up to develop a biosimilar of Soliris (eculizum...
by Lee Hye-seon  |  2019-06-27 17:14
Eutilex unveils immunotherapy development strategy
Eutilex presented its immunotherapy development strategy during the "Global...
by Lee Han-soo  |  2019-06-27 16:51
Voluntary nullifications of drug license tripled in H1
An increasing number of pharmaceutical companies voluntarily canceled the l...
by Lee Hye-seon  |  2019-06-26 14:25
Seoul Pharma to export erectile dysfunction treatment to Azerbaijan
Seoul Pharmaceuticals has signed an agreement with Loghman Pharmaceutical o...
by Lee Han-soo  |  2019-06-26 13:58
Novartis’ Tasigna confirms long-term success for chronic myelogenous leukemia
Novartis has reaffirmed the long-term success of Tasigna (Ingredient: Nilot...
by Lee Han-soo  |  2019-06-26 11:39
Huons Global launches new BTX in Korea
Huons Global plans to launch a new botulinum toxin (BTX) product in Korea. ...
by Lee Han-soo  |  2019-06-26 10:52
Hanmi, Sanofi revise accord on co-developing diabetes drug
Hanmi Pharmaceutical said it has signed a revised agreement with Sanofi to ...
by Lee Han-soo  |  2019-06-25 17:36
‘Imbruvica raised survival rate of mantle cell lymphoma patients’
“Imbruvica works better than any other existing chemotherapy in relapsed an...
by Kim Yun-mi  |  2019-06-25 15:34
CHA Biotech to transfer SCRMI’s shares, technology to AIRM
CHA Biotech said that it would transfer shares and technologies of Stem Cel...
by Lee Han-soo  |  2019-06-25 15:25
Regulator OKs P3 trial for Eisai's Alzheimer treatment
The Ministry of Food and Drug Safety has approved the phase 3 clinical tria...
by Lee Han-soo  |  2019-06-25 14:09
Novartis’ Cosentyx shows durable, comprehensive treatment for psoriatic disease
Novartis has released new data on five-year long-term immunogenicity and in...
by Lee Han-soo  |  2019-06-25 14:09
Back to Top